Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

Learn more about TECENTRIQ®▼ (atezolizumab), a cancer immunotherapy treatment, by clicking on the respective indication of interest:

 

HCC

Lung

Hepatocellular carcinoma1,2

Tecentriq®, in combination with Avastin® (bevacizumab), is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Please click here for more information

Non-small cell lung cancer (NSCLC):1-2

Tecentriq is indicated as 1L monotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC ) whose tumours have a PD- L1 expression ≥ 50 % tumour cells (TC ) or ≥10% tumour-infiltrating immune cells (IC ) and who do not have EGFR mutant or ALK- positive NSCLC.
Please click here for more information

Tecentriq®, in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq®, in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

Tecentriq® as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq®.

Tecentriq®, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC

Small cell lung cancer (SCLC):1,2

Tecentriq®, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

 

Triple-negative breast cancer (TNBC):1,2

Tecentriq® in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. 

 

Urothelial carcinoma (UC): 1,2

Tecentriq® as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma:

  • after prior platinum-containing chemotherapy, or
  • who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%

 

References:

  1. Tecentriq Summary of Product Characteristics – Great Britain
  2. Tecentriq Summary of Product Characteristics – Northern Ireland


M-GB-00004982
Date of preparation: October 2021